<DOC>
	<DOCNO>NCT02489201</DOCNO>
	<brief_summary>This open-label , one-center , noncomparative , two-stages phase 1B trial assess tyrosine kinase inhibitor donafenib tosylate tablet ( 400 mg/d,200mg bid ) patient advance , inoperable oesophageal cancer progress chemotherapy . The primary endpoint safety.The secondary endpoint tumor response progression-free survival .</brief_summary>
	<brief_title>A Study Donafenib Monotherapy Advanced Oesophageal Cancer</brief_title>
	<detailed_description>This open-label , noncomparative , two-part phase 1B trial recruit patient advanced , inoperable oesophageal cancer . The primary objective assess safety donafenib tosylate tablet .The secondary objective estimate tumor response , progression-free survival , duration response , disease control rate ( response plus stable disease ) ; evaluate change quality life ( QoL ) ; This study 2-stages designing . The investigator plan enroll 19 patient first stage study . The investigator start secondary stage study disease control rate &gt; =8/19 .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>All patient provide write , informed consent . Have histologically confirm advanced oesophageal squamouscell carcinoma , type I/II Siewert junctional tumour . Have receive two previous chemotherapy regimen ( Platinum contain regimen &amp; Paclitaxel / docetaxel contain regimen ) . Have Eastern Cooperative Oncology Group Performance status 01 . Have ability swallow tablet . contraindication sorafenib donafenib . Have either measurable evaluable lesion CT . Patients brain metastasis . Patients receive cytotoxic chemotherapy , immunotherapy hormonal therapy , radiotherapy site measurable evaluable disease within previous 4 week . Patients evidence clinically active interstitial lung disease abnormal blood result predefined criterion ( serum bilirubin &gt; 1.5 time upper limit reference range , aspartate alanine aminotransferase &gt; 2.5 time upper limit normal demonstrable liver disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>donafenib</keyword>
</DOC>